TOPLINE: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses. METHODOLOGY: GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence … Read more
TOPLINE: Oral lamivudine, an inflammasome inhibitor originally approved for suppressing HIV, was a relatively safe and effective treatment for improving visual acuity in adults with center-involving diabetic macular edema, a serious complication of diabetic retinopathy. METHODOLOGY: Researchers conducted a clinical trial to assess the effectiveness of oral lamivudine vs placebo in improving visual acuity in … Read more
Key Points Infants born to mothers with pregestational diabetes face a higher risk of NICU admission. Research highlights teh importance of managing diabetes during pregnancy. Understanding risk factors can improve neonatal care and outcomes. New Study Links Pregestational Diabetes to Increased NICU Admissions Updated May 22, 2025 A recent study published in the European … Read more
TOPLINE: An emergency department (ED)–based alert led to a higher rate of A1c testing among patients with diabetes overdue for routine monitoring but did not significantly improve long-term glycemic control. METHODOLOGY: In this retrospective study, the researchers analyzed 348,490 ED visits by patients with diabetes from January 2017 to September 2023. In November 2017, an … Read more
TOPLINE: Patients with type 2 diabetes (T2D) who received glucagon-like peptide 1 (GLP-1) receptor agonists had a significantly lower risk of developing local or systemic complications — even if they developed acute pancreatitis — and showed more than a 50% reduction in risk for all-cause mortality than those who did not receive these medications. METHODOLOGY: … Read more
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carol H. Wysham, MD: Hello. I’m Dr Carol Wysham. Welcome to season 3 of the Medscape InDiscussion Type 2 Diabetes podcast series. Today, we’ll discuss chronic kidney … Read more
TOPLINE: Increased levels of urine metabolites choline and dimethylglycine were independently associated with an increased risk for renal events and all-cause mortality in patients with type 2 diabetes (T2D), with evidence suggesting that tubular stress partly mediated the link between disrupted choline metabolism and the gradual decline in kidney function in this population. METHODOLOGY: Although … Read more
Primary care practices are seeing an uptick in patients inquiring about glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications due to both media hype and sizzle-reel stories they see on social media. If your patients start an appointment with their own agenda about wanting a prescription for these medications, there are ways to pause the … Read more
Sotagliflozin Shows Promise for Diabetes Management,Despite FDA Hurdles New research presented at the American Association of clinical Endocrinology (AACE) Annual Meeting 2025 suggests that sotagliflozin (Inpefa) can lower A1C levels and reduce body weight in individuals wiht type 2 diabetes. However, the benefits appear to be less pronounced in patients with moderate-to-severe chronic kidney disease … Read more
Emerging data about benefits of the newer weight-loss drugs for some chronic skin conditions suggests their potential use in dermatology, as well as a role for dermatologists in obesity management. Glucagon like peptide 1 receptor agonist (GLP-1 RA) medications began as treatments for type 2 diabetes (T2D), then emerged as weight-loss drugs. The newer generation … Read more